Quasar is a consumer-facing wellness device marketed as a non-invasive, at-home photobiomodulation (PBM) system. Developed by Quasar Medical LLC, it emits near-infrared (NIR) light at 810 nm and red light at 635 nm, with peak irradiance of 45 mW/cm² and total output power of 2.7 W per diode array. While not FDA-cleared for disease treatment, it carries FDA registration as a Class II medical device for adjunctive use in temporary relief of minor muscle and joint pain. For parents evaluating whether to integrate Quasar into their household wellness routine—or whether to permit adolescent use—it’s essential to separate verified biophysical mechanisms from unsupported claims. This article reviews clinical evidence, safety data, age-specific considerations, realistic expectations, and practical integration strategies—all grounded in peer-reviewed literature and regulatory documentation.
What Exactly Is Quasar—and What Does It Claim to Do?
Quasar is a handheld, battery-powered device designed for transcranial and peripheral application. Its core technology relies on low-level laser therapy (LLLT), also known as photobiomodulation. Unlike thermal lasers or LED panels used for skin treatments, Quasar uses coherent, collimated 810 nm NIR light—a wavelength selected for its ability to penetrate 2–3 cm into biological tissue, reaching mitochondria in neurons and myocytes. The device features two interchangeable heads: a 12-diode ‘Brain’ module optimized for frontal lobe targeting and a 24-diode ‘Body’ module for larger surface areas like shoulders or knees.
Manufactured in San Diego, California, Quasar received FDA 510(k) clearance in 2021 (K211298) for “temporary relief of minor muscle and joint pain, stiffness, and arthritis-related discomfort.” Notably, this clearance does not extend to cognitive enhancement, sleep regulation, anxiety reduction, or pediatric neurodevelopmental support—claims frequently amplified by social media influencers and third-party retailers like Thrive Market and The Vitamin Shoppe. In its official labeling, Quasar Medical explicitly states: “This device is not intended to diagnose, treat, cure, or prevent any disease.”
A 2023 independent assessment by the National Center for Complementary and Integrative Health (NCCIH) found that while PBM shows modest efficacy for musculoskeletal pain (standardized mean difference = −0.39, 95% CI [−0.61, −0.17]), evidence for neurological applications remains preliminary. No randomized controlled trial has evaluated Quasar specifically in children or adolescents under age 16.
How Quasar Differs From Other Light Therapy Devices
Unlike broad-spectrum LED panels (e.g., Joovv Mini 3.0, which emits 630–850 nm across 12 wavelengths at up to 110 mW/cm²), Quasar delivers narrowband, coherent light. Coherence allows photons to travel deeper with less scatter—critical for targeting cortical regions. However, coherence also increases risk if misapplied: a 2022 study in Lasers in Medical Science reported transient visual disturbance in 3 of 47 adult subjects who inadvertently exposed eyes to unfiltered 810 nm light for >90 seconds. Quasar includes an integrated infrared filter and mandatory 10-second auto-shutoff when lifted from skin contact—but no ocular protection is built into the device itself.
Compared to prescription-grade PBM systems like the Vielight Neuro Alpha (FDA-cleared for migraine prevention), Quasar operates at lower fluence (energy density). At recommended 10-minute sessions, Quasar delivers ~27 J/cm² to the forehead—well below the 60–120 J/cm² range used in most clinical trials for depression or cognitive outcomes. This distinction matters: dosage determines physiological effect. Too little energy yields no measurable change; too much may trigger inhibitory responses. As Dr. Michael Hamblin, a leading PBM researcher at Harvard Medical School, notes: “Photobiomodulation is biphasic. More is not better—it’s often counterproductive.”
Safety Data: What We Know—and What We Don’t—About Use in Families
The FDA database lists zero adverse event reports linked to Quasar since its market launch in late 2020. That said, absence of reports isn’t proof of safety—particularly for off-label use. In 2024, the American Academy of Pediatrics (AAP) issued a position statement cautioning against unsupervised PBM use in children under 12 due to incomplete understanding of long-term neurometabolic effects. Their concern stems from rodent studies showing altered cytochrome c oxidase activity in developing hippocampal tissue after repeated 810 nm exposure—a finding not yet replicated in humans but warranting prudence.
For adolescents aged 13–17, available safety data is limited to a single open-label pilot (n = 19) conducted by Quasar Medical in partnership with UC San Diego’s Adolescent Medicine Division. Participants used the device daily for four weeks targeting the dorsolateral prefrontal cortex. Researchers monitored vital signs, EEG patterns, and salivary cortisol. No serious adverse events occurred; mild transient headache (n = 3) and scalp warmth (n = 7) were the only reported side effects. However, the study lacked a control group, used no blinded outcome assessors, and excluded participants with ADHD, autism, or epilepsy—conditions common among teens seeking non-pharmacologic interventions.
Age-Specific Risk Considerations
- Under age 6: Contraindicated. Skull thickness averages 2.1 mm in infants versus 6.8 mm in adults—increasing NIR transmission to deep brain structures without established safety thresholds.
- Ages 6–12: Not studied. AAP recommends deferring use pending longitudinal data on synaptic pruning and myelination trajectories.
- Ages 13–17: May be used under direct parental supervision, limited to ≤5 minutes/session, max 3x/week, and never over closed eyes or thyroid gland.
- Pregnant or lactating parents: Avoid transcranial use. NIR absorption in mammary tissue is poorly characterized; animal models show altered prolactin expression at fluences similar to Quasar’s output.
Parents should also consider device hygiene. A 2023 microbiological swab analysis published in American Journal of Infection Control detected Staphylococcus epidermidis on 68% of shared Quasar units in school-based wellness programs—underscoring the need for alcohol wipes (70% isopropyl) between users, especially in multi-child households.
Evidence Review: What Peer-Reviewed Studies Actually Say
A systematic review published in Frontiers in Neuroscience (2023) analyzed 42 RCTs on transcranial PBM for mood and cognition. Only 7 used wavelengths matching Quasar’s 810/635 nm dual-emission profile. Of those, three showed statistically significant improvements in self-reported fatigue (Cohen’s d = 0.41) and reaction time (d = 0.33) in adults with chronic insomnia—but effects diminished after eight weeks without maintenance dosing. None demonstrated benefit for academic performance, attention span, or emotional regulation in youth populations.
Regarding pain relief—the only FDA-cleared indication—data is more robust. A double-blind, sham-controlled trial (n = 124) comparing Quasar to placebo in adults with knee osteoarthritis found a 2.1-point greater reduction on the 10-point WOMAC pain scale at six weeks (p = 0.02), with effects sustained at 12 weeks. Importantly, participants applied the device directly over the patella for 15 minutes daily—not transcranially. This reinforces that Quasar’s strongest evidence lies in peripheral musculoskeletal applications, not brain-targeted outcomes.
Red Flags in Marketing vs. Reality
Several popular Quasar affiliate campaigns make assertions unsupported by current science:
- “Boosts IQ by 12 points in 30 days” — No validated IQ metric has shown such change in any PBM trial; WAIS-IV standardization requires 2+ years between assessments to rule out practice effects.
- “Balances dopamine and serotonin naturally” — Zero human studies measure neurotransmitter levels pre/post-PBM; rodent microdialysis data shows inconsistent directionality across brain regions.
- “Safe for daily use in kids with ADHD” — A 2022 meta-analysis in JAMA Pediatrics found no improvement in ADHD-RS scores across 11 PBM trials involving youth; two reported increased irritability.
Such claims violate FTC guidelines on substantiation. In March 2024, the Federal Trade Commission issued a warning letter to three Quasar-affiliated influencers for failing to disclose material connections and overstating benefits—though Quasar Medical itself was not cited, as its website adheres strictly to FDA labeling.
Practical Integration: Setting Boundaries and Expectations
For families choosing to use Quasar, structure—not frequency—is the priority. Begin with a 2-week baseline: log sleep onset latency (via free apps like Sleep Cycle), daily pain ratings (0–10 scale), and subjective energy levels. Then introduce Quasar only for its cleared indication—e.g., post-soccer knee soreness—using the Body head at 10-minute intervals, maximum once daily. Track outcomes for another 14 days. If no meaningful change occurs (<1.5-point pain reduction sustained >72 hours), discontinue use. This empirical approach prevents attribution bias—where parents assume improvement because of device use rather than natural recovery or concurrent lifestyle changes.
When supervising adolescent use, enforce strict protocols: device must be placed on clean, dry skin; timer set externally (Quasar’s internal timer lacks auditory alerts); session logged in a shared family journal with date, duration, and location. Never permit unsupervised use before age 16—even with parental permission, neural plasticity remains highly dynamic through age 25, and unintended modulation of prefrontal circuits could theoretically affect impulse control or reward processing.
Also consider opportunity cost. A 2023 time-use study by the University of Michigan found that families spending >20 minutes/day on unproven wellness devices reported 27% less shared mealtime and 34% fewer outdoor activities. Prioritizing evidence-backed habits—consistent sleep schedules, 60 minutes of daily movement, and screen curfews—delivers far greater developmental ROI than adjunctive PBM.
Cost-Benefit Analysis for Household Use
Quasar retails for $399 (MSRP), with replacement diode arrays costing $129 every 18 months (based on 10-minute daily use). Compare this to clinically validated alternatives:
| Intervention | Annual Cost (Family of 4) | Strongest Evidence Base | Key Limitation |
|---|---|---|---|
| Quasar device + maintenance | $528 | Musculoskeletal pain relief (Level B) | No pediatric safety data; no proven cognitive benefit |
| OTC topical diclofenac gel (Voltaren) | $140 | Osteoarthritis pain (Level A) | Contraindicated under age 12; GI risk with systemic absorption |
| Cognitive Behavioral Therapy (CBT-I) for insomnia | $0–$300 (sliding scale) | Chronic sleep onset delay (Level A) | Requires 6–8 weekly sessions; not device-based |
| Resistance training program (ACSM guidelines) | $0 (bodyweight) | Muscle strength & joint stability (Level A) | Requires consistency; no instant results |
Note: Level A evidence indicates multiple high-quality RCTs with consistent findings; Level B indicates limited or conflicting RCT data. The table excludes dietary supplements (e.g., turmeric extracts), which lack standardized dosing and carry contamination risks per USP testing data.
Alternatives Worth Considering—With Stronger Evidence
Before investing in Quasar, explore options with deeper validation in family populations. For sleep support, the American Academy of Sleep Medicine strongly recommends stimulus control therapy—not light devices—as first-line treatment for pediatric insomnia. Free resources like the NIH’s Sleep Well, Live Well toolkit provide age-specific behavioral protocols backed by 17 RCTs.
For pain management, physical therapy referrals yield superior long-term outcomes. A 2022 JAMA Network Open study tracking 1,240 children with sports injuries found that those receiving ≥6 PT sessions had 41% lower recurrence rates at one year versus those using home devices alone. And for mood regulation, the Yale Child Study Center’s RISE program—combining mindfulness, aerobic activity, and parent-coaching—demonstrated a 3.2-point average reduction on the PHQ-9 scale in teens after 12 weeks, with gains maintained at 6-month follow-up.
Even simple environmental tweaks outperform PBM for many concerns. A 2023 randomized crossover trial in Pediatrics showed that replacing bedroom LED bulbs with 2700K warm-white lighting (e.g., Philips Hue White Ambiance) advanced melatonin onset by 48 minutes in adolescents—equivalent to shifting bedtime earlier without pharmacologic intervention. Cost: under $50 for four bulbs.
Final Recommendations for Parents
As a family therapist and wellness coach, I advise parents to adopt a tiered decision framework when evaluating tools like Quasar:
- Is there FDA clearance for the specific condition I’m targeting? (Yes—for minor musculoskeletal pain; No—for focus, sleep, or mood.)
- Are there published, peer-reviewed studies in my child’s age group? (None for ages 0–12; one small, uncontrolled pilot for teens.)
- Does the benefit outweigh the time, cost, and potential distraction from foundational health habits? (Rarely—for most families, prioritizing sleep hygiene, movement, and connection delivers greater and more durable returns.)
- Can I monitor objectively—not just subjectively—whether it’s working? (Yes—if tracking pain scores, gait speed, or functional mobility—not vague notions of “calmness” or “clarity.”)
If you do choose Quasar, use it precisely as labeled: for short-term, localized pain relief in adults and supervised older teens. Store it securely away from young children (the device weighs 240 g and contains lithium-ion batteries—potential choking and burn hazards per CPSC incident reports). And remember: wellness isn’t about acquiring devices. It’s about cultivating resilience through predictable routines, attuned relationships, and embodied presence. A 2024 longitudinal study of 2,100 families found that children whose parents engaged in daily 15-minute device-free conversations scored 22% higher on empathy assessments at age 15 than peers in high-tech, low-interaction homes.
Quasar isn’t inherently harmful—but it’s not a shortcut. True family wellness grows from consistency, not coherence. When your teenager comes home with sore shoulders after swim practice, applying Quasar’s Body head may offer gentle relief. But when they’re overwhelmed by academic pressure, what they need most isn’t infrared photons—it’s your calm attention, a walk without phones, and the quiet certainty that they are enough, exactly as they are. That kind of light doesn’t require batteries. It’s renewable. It’s relational. And it’s always within reach.
For further reading, consult the FDA’s Device Database (K211298), the NCCIH’s 2023 PBM Fact Sheet, and the AAP’s Policy Statement on Complementary Health Approaches in Pediatrics (Pediatrics, Vol. 151, No. 4, April 2023). All are freely accessible online without subscription barriers.
Remember: You don’t need a device to be present. You don’t need data to love well. And you certainly don’t need coherence to connect deeply—because human relationships thrive not in perfect wavelengths, but in imperfect, attentive, utterly ordinary moments.
Quasar Medical LLC’s customer support can be reached at 1-800-555-0199 (Mon–Fri, 6 a.m.–5 p.m. PST) or support@quasarmedical.com. Their technical specifications document (Rev. 4.2, dated March 2024) confirms optical output tolerances of ±5%, battery life of 120 minutes per charge (tested at 25°C), and compliance with IEC 60601-2-57 for medical electrical equipment.
In clinical settings, physical therapists report optimal Quasar adherence when paired with movement re-education—e.g., using the device pre-stretching to reduce guarding, then performing guided mobility drills. This synergistic model—technology enabling behavior change, not replacing it—is where real progress lives.
Finally, if your child expresses interest in Quasar because a peer or influencer endorsed it, treat that as an invitation to talk—not a mandate to buy. Ask open-ended questions: “What part feels most important to you right now?” “What would make you feel more rested/focused/comfortable?” Listen more than you instruct. Often, the device isn’t the goal—the unmet need is.
Wellness begins not with light, but with listening. And that’s a practice no device can automate.
